Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide and Bone Turnover in Postmenopausal Women With Type 2 Diabetes
NCT01381926Phase 4Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2011
- Primary completion
- Aug 2015
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by University of Alabama at Birmingham. Primary endpoint: Changes in Bone Resorption Markers at 20 weeks. Started Feb 2011; status: terminated.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01381926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381926.